The USPSTF concludes with high certainty that the benefits of screening every 3 years with cytology alone in women aged 21 to 29 years substantially outweigh the harms. The USPSTF found convincing evidence that screening with cervical cytology alone, primary testing for high-risk HPV types (hrHPV testing) alone, or in combination at the same time (cotesting) can detect high-grade precancerous cervical lesions and cervical cancer. 2 Strategies that aim to ensure that all women are appropriately screened and receive adequate follow-up are most likely to succeed in further reducing cervical cancer incidence and mortality in the United States. 1 Most cases of cervical cancer occur among women who have not been adequately screened.
The number of deaths from cervical cancer in the United States have decreased substantially since the implementation of widespread cervical cancer screening and continue to decline, from 2.8 per 100,000 women in 2000 to 2.3 deaths per 100,000 women in 2015.
#SATISFACTORY UPDATE 4 FULL#
Early-stage cervical cancer may be treated with surgery (hysterectomy) or chemotherapy.įor a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please go to. High-grade cervical lesions may be treated with excisional and ablative therapies. Clinicians should focus on ensuring that women receive adequate screening, appropriate evaluation of abnormal results, and indicated treatment, regardless of which screening strategy is used. Screening with cervical cytology alone, primary testing for hrHPV alone, or both at the same time (cotesting) can detect high-grade precancerous cervical lesions and cervical cancer. Women with these risk factors should receive individualized follow-up. Certain risk factors further increase risk for cervical cancer, including HIV infection, a compromised immune system, in utero exposure to diethylstilbestrol, and previous treatment of a high-grade precancerous lesion or cervical cancer. Screen for cervical cancer every 3 years with cytology alone, every 5 years with hrHPV testing alone, or every 5 years with cotesting.Īll women aged 21 to 65 years are at risk for cervical cancer because of potential exposure to high-risk HPV types (hrHPV) through sexual intercourse and should be screened.
Screen for cervical cancer every 3 years with cytology alone. Women younger than 21 years, women older than 65 years with adequate prior screening, and women who have had a hysterectomy See the Clinical Considerations section for discussion of adequate prior screening and risk factors that support screening after age 65 years. The USPSTF recommends against screening for cervical cancer in women older than 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer. The USPSTF recommends against screening for cervical cancer in women who have had a hysterectomy with removal of the cervix and do not have a history of a high-grade precancerous lesion (ie, cervical intraepithelial neoplasia grade 2 or 3) or cervical cancer. The USPSTF recommends against screening for cervical cancer in women younger than 21 years. See the Clinical Considerations section for the relative benefits and harms of alternative screening strategies for women 21 years or older.
For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with hrHPV testing in combination with cytology (cotesting). The USPSTF recommends screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years.
0 kommentar(er)
